Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
255.71+0.58 (+0.23%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 249.62 |
| Open | 251.10 |
| Bid | 252.00 x 800 |
| Ask | 255.09 x 800 |
| Day's Range | 250.50 - 257.00 |
| 52 Week Range | 207.33 - 276.69 |
| Volume | 2,272,190 |
| Avg. Volume | 2,765,598 |
| Market Cap | 147.238B |
| Beta (5Y Monthly) | 0.74 |
| PE Ratio (TTM) | 20.77 |
| EPS (TTM) | 12.31 |
| Earnings Date | Apr 28, 2021 - May 03, 2021 |
| Forward Dividend & Yield | 7.04 (2.75%) |
| Ex-Dividend Date | May 14, 2021 |
| 1y Target Est | 255.93 |
- PR Newswire
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses.
- TheStreet.com
Amgen Looks Ready for an Upside Breakout
Amgen has been in a long-term uptrend but the stock has been stalled for the past year. The indicators I favor are looking more positive so let's check out the charts to see if this is the time to buy.
© 2021 Verizon Media. All rights reserved.
